(Q40995312)

25 September 2017

1 reference

title

Chronic myelogenous leukemia: a review (English)

1 reference

25 September 2017

1 reference

Cortes JE

1

1 reference

25 September 2017

Talpaz M

series ordinal

2

1 reference

25 September 2017

Kantarjian H

series ordinal

3

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 May 1996

1 reference

American Journal of Medicine

25 September 2017

published in

1 reference

25 September 2017

volume

100

1 reference

25 September 2017

issue

5

1 reference

25 September 2017

page(s)

555-570

1 reference

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Cancer incidence and survival in patients 65 years of age and older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Case report of vasopressin-responsive diabetes insipidus associated with chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Characteristics of accelerated disease in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Chronic granulocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Cyclic leukocytosis and long survival in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Histological classification of chronic granulocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

An extrinsic factor controls neutrophil alkaline phosphatase synthesis in chronic granulocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Extramedullary presentation of the blast crisis of chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Staging of chronic myeloid leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

The molecular genetics of Philadelphia chromosome-positive leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Acute leukaemia in bcr/abl transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Requirement for c-ras proteins during viral oncogene transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Differential complementation of Bcr-Abl point mutants with c-Myc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Treatment of excessive thrombocythemia in chronic myeloid leukemia by thrombocytopheresis and intravenous Thio-TEPA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Clinical toxicity of interferons in cancer patients: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Marrow transplantation for the treatment of chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Mobilization of cytogenetically 'normal' blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome-negative cells in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Autografting in chronic myelogenous leukemia followed by immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Clinical detection of BCR-abl fusion by in situ hybridization in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900061-7

10.1016/S0002-9343(96)00061-7

7 January 2021

Identifiers

DOI

1 reference

25 September 2017

1 reference